Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the […]
Eli Lilly Retatrutide Phase 3 Results at ADA 2026 Read More »
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View FTX-6058 and Pociredir FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug FTX-6058 and Pociredir showed strong early sickle
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug Read More »
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View IQVIA Wegovy Pill Data Oral GLP-1 May Bring New Patients Into the Market IQVIA’s early Wegovy pill data suggests oral GLP-1 drugs may expand the obesity
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion Read More »
Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View Fulcrum’s Pociredir Collapse How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug A data-heavy Witfire Breaking Case
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk | Witfire Elite View Witfire Elite Investment Case Studies Strategy Investment News Investment Witfire Elite View Lilly’s Germany Investment Cut Why Pharma Capital Is Starting to Vote Against Policy Risk Eli Lilly is reportedly halving its planned €2.3 billion Germany investment,
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection | Witfire Elite View Witfire Elite Philippines Pharma Watch Case Studies Strategy Breaking Analysis Philippines Pharma Watch Witfire Elite View Philippines AI Liver Cancer Breakthrough How the CANDLE Study Could Change Early Detection A Witfire Breaking Analysis on how the Philippines’ CANDLE
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections A data-rich pharma case study on how IQVIA’s early
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections Read More »
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA’s Digital Liver Break How AI Toxicology Could Change Drug Development Before Phase I FDA accepted the first in silico
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The China Biotech Pipeline Grab How Big Pharma Started Buying Innovation From China A data-heavy pharma case study on how Pfizer, BMS,
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China Read More »
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A
